BOSTON—AdvaMed, the Medtech Association, concluded The MedTech Conference 2026, convening more than 4,470 attendees from 2,050 companies from 40 countries for the global medtech industry’s premier annual gathering.
AdvaMed® urges DOJ to remove outdated rules that block medtech innovation and limit access to lifesaving technology.
AdvaMed® President and CEO Scott Whitaker describes the importance of engaging patients in every stage of medtech innovation.
AdvaMed®’s Deputy General Counsel and Senior, VP of Legal, Pat Fogarty, joined Jack Kalavritinos, host of Capital Forum, and Jonathan Turner, Global Head of Compliance, Privacy and Governance, Zoll Medical,…
These arrangements to advance value-based care are designed to increase shared accountability among shareholders for quality of, access to and/or the total cost of care.
The AdvaMed® Board of Directors has approved revisions to the AdvaMed® Code of Ethics on Interactions with Health Care Professionals in the U.S., effective June 1, 2022.
AdvaMed®, the world’s largest trade organization representing medical technology manufacturers, today announced that its board of directors has unanimously approved revisions to the AdvaMed® Code of Ethics on Interactions with Health Care Professionals.
The U.S. health care system is transitioning from a fee-for-service and fee-for-product (volume-based) model to value-based paradigm to deliver more coordinated, high-quality, affordable health care.
AdvaMed® advocates on a global basis for the highest ethical standards and works to facilitate a legal environment that fosters medical technology innovation and timely patient access to safe and effective…
Unequal access to medical technologies and, more broadly, health care services continues to persist – often disproportionately impacting the lives of racial and ethnic minorities.